CEO and Co-Founder, MedAvante, Inc
Princeton, NJ

Paul Gilbert has 30 years of leadership, strategy, and innovation experience at best-practice organizations including Johnson & Johnson, Arm & Hammer, Booz Allen and Gillette. He has successfully scaled up companies in both consumer and business markets with an emphasis on innovating new markets.

As CEO of MedAvante, Paul and his co-founder, Amy Ellis, envisioned, launched, and globalized two new-to-world innovations that transformed psychiatric and neurological trials across a 40 country footprint. The first, Central Ratings, solved the pharmaceutical industry’s intractably high rate of failed mental health trials. MedAvante reduced trial failure rates of known effective psychiatric treatments from 50% to under 15%. The second innovation, electronic clinical outcome assessments (eSource), led the pharma industry’s transition from error-prone paper-based central nervous system trials to accurate digitally-enabled trials. His leadership focus has been on developing and communicating vision; mobilizing exceptional talent, capital and resources; and catalyzing ecosystems to effect change. Paul’s GlassDoor rating is 98% versus the category average of 51%.

Paul has served most recently on the boards of Growth Philanthropy Network (current), Derma Sciences, a publicly traded tissue regeneration company recently acquired, and the prestigious non-profit International Longevity Centre Global Alliance (acquired by Columbia University). Paul has been invited to present on innovation multiple times at Princeton and Wharton and is a strategic advisor to young innovative companies. In 2012, he was awarded the Ernst & Young Lifesciences Entrepreneur of the Year.

Paul graduated magna cum laude from Bowdoin College where he was named a James Bowdoin Scholar, and received his MBA from Harvard University.

Profile of Impact: Reimagining the Delivery of Mental Health

Partner: Amy Ellis